VivoSeq
Neurology

Epilepsy

187

Pipeline Programs↗

60

Active Trials↗

74

Companies Involved↗

Epilepsy is a highly competitive landscape with 187 programs across 74 companies. The most active players are Iperboreal Pharma Srl, Egetis Therapeutics, Shanghai Zhimeng Biopharma, Inc.. 56 therapies are approved with 28 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

81/100

Pipeline Velocity

41/100

Mech. Concentration

11/100

Completion Rate

82/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Iperboreal Pharma Srl

1 program

Phase 1E

Egetis Therapeutics

1 program

Phase 1S

Shanghai Zhimeng Biopharma, Inc.

2 programs

Phase 2E

ES Therapeutics Australia Pty Ltd

2 programs

Phase 2A

Aquestive Therapeutics

1 program

Phase 2Biogen logo

Biogen

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical32

Eslicarbazepine Acetate

Sumitomo Pharma America, Inc.

Divalproex Sodium

Teva

Vimpat

UCB

Keppra XR

UCB

Briviact

UCB

Phase 125

Alprazolam

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Memantine Hydrochloride

Forest Laboratories

Diazepam

Akero Therapeutics

Gliclazide

Merck & Co.

Methylprednisolone Sodium Succinate

Massachusetts Eye and Ear Infirmary

Phase 246

Galcanezumab

Eli Lilly

Ketamine Hydrochloride

Boehringer Ingelheim

Melatonin

Neurim Pharmaceuticals Ltd.

Ataluren

PTC Therapeutics

UCB0599

UCB

Phase 328

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Naloxone

Scienture

Brivaracetam

UCB

Lemborexant

Eisai

Ganaxolone

Immedica Pharma AB

Approved56

Nifedipine

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lacosamide

UCB

Warfarin

Abbott

Gabapentin

Viatris Specialty LLC

Perampanel

Catalyst Biosciences

Analysis

Modality Breakdown

96%

Small molecule

204 of 212 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody42%Cell therapy31%Vaccine1<1%

Small molecule leads; the ring shows all 212 classified programs, each share of the total. Modality classified for 99% of 222 pipeline programs.

Analysis

Trial Status

337

clinical trials

Completed181 · 54%
Unknown status48 · 14%
Recruiting39 · 12%
Terminated25 · 7%
Withdrawn14 · 4%
Not yet recruiting11 · 3%
Other19 · 6%

Clinical Trials

Trial Activity

337 trials

Levetiracetam Three Times Daily in Epilepsy
Recruiting·—·Phase 3·NCT07490769·120 enrolled
Exogenous Ketone Esters for Drug Resistant Epilepsy
Recruiting·SSohag University·Phase 2/3·NCT05670847·60 enrolled
Lemborexant Treatment of Insomnia Linked to Epilepsy
Recruiting·UUniversity of Manitoba·Phase 3·NCT06262594·26 enrolled
Imaging of Neuro-Inflammation and the Risk for Post-Traumatic Epilepsy
Recruiting·UUniversity of California, Davis·Phase 1·NCT03999164·30 enrolled
The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy
Recruiting·—·Phase 2·NCT05019885·8 enrolled
BMB-101 in Absence Epilepsy and DEE
Recruiting·BBright Minds Biosciences Pty Ltd·Phase 2·NCT06401538·20 enrolled
An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy
Recruiting·SShanghai Zhimeng Biopharma, Inc.·Phase 2·NCT07238868·144 enrolled
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
Recruiting·NNeuroPro Therapeutics, Inc.·Phase 2·NCT06769659·10 enrolled
Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery
Recruiting·—·Phase 1·NCT06280092·5 enrolled
Precision Medicine in the Treatment of Epilepsy
Recruiting·—·N/A·NCT05450822·550 enrolled
Ketogenic Diet in Pediatric Intractable Epilepsy
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT06310954·59 enrolled
Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy
Recruiting·UUniversity of Alberta·Phase 2·NCT06483061·50 enrolled
Ketogenic Diet for New-Onset Absence Epilepsy
Recruiting·JJohns Hopkins University·Phase 3·NCT04274179·40 enrolled
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
Recruiting·—·Phase 2·NCT05104983·64 enrolled
Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)
Recruiting·XXuanwu Hospital, Beijing·Phase 1·NCT06719791·15 enrolled
Page 1 of 23

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)